The Canadian Cancer Trials Group found that extending hormone therapy keeps breast cancer at bay.
Many post-menopausal women with early breast cancer are treated with a type of hormone therapy called an aromatase inhibitor for 5 years to prevent the cancer from coming back. A clinical trial by the Society-supported Canadian Cancer Trials Group showed that extending this treatment to 10 years reduced the risk of recurrence even more. This research will help women and their doctors make more informed long-term treatment choices.
Learn more about the impact of our research, supported by your donations.
Reference: ASCO Annual Meeting, June 2016; New England Journal of Medicine, July 2016
Pictured: Canadian Cancer Trials Group researcher Dr Wendy Parulekar